literature

HIV mutation literature information.

Prevalence and patterns of drug-resistance mutations among HIV-1 patients infected with CRF07_BC strains in Sichuan province, China.

PMID: 25160759 2014 Virologica Sinica

Abstract: Only one participant in the drug-naive group had a drug-resistance mutation (M46L), compared with 31.73% of those in whom ART had failed.

A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

PMID: 25259833 2014 AIDS (London, England)

Result: Of the 243 patients who received one or more protease inhibitors, 32 (13%) had a study-defined protease inhibitor-resistance mutation most commonly L10F, K20T, V32I, L33F, M46I/L, I47V/A, I50L, F53L, I54V/L, Q58E, L76V, V82A/C, I84V, L89V, and L90M.

A significant reduction in the frequency of HIV-1 drug resistance in Quebec from 2001 to 2011 is associated with a decrease in the monitored viral load.

PMID: 25295725 2014 PloS one

Result: The most common primary mutations associated with ARV resistance in TE individuals ( Figure 2 ) were NRTIs: M184I/V (51.1%) and thymidine analog mutations (TAM) from TAM1 pathway (41L/210W/215Y; 17%), representing 76.2% of all TAM pathways (data not shown); NNRTIs: K103N (24.9%); PIs: L90 M (21.1%), V82 (16.8%), M46I/L (18.2%).

Minority drug-resistant HIV-1 variants in treatment naive East-African and Caucasian patients detected by allele-specific real-time PCR.

PMID: 25333961 2014 PloS one

Result: Direct sequencing identified two patients with additional DRM (L100IL, M46L) (Table 2).

Table: M46L

Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey.

PMID: 25397495 2014 Journal of the International AIDS Society

Abstract: RESULTS: The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M).

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.

PMID: 25397500 2014 Journal of the International AIDS Society

Table: M46L

[Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].

PMID: 25492654 2014 Mikrobiyoloji bulteni

Abstract: Detected mutations were as follows: M41L, K70E, M184V, L210W and T215C/D/S, responsible for nucleoside RT inhibitor (NRTI) resistance; K103N/S and Y181C, responsible for non-nucleoside RT inhibitor (NNRTI) resistance; M46L and L90M, responsible for protease inhibitor (PI) resistance.

HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China.

PMID: 25510523 2014 BMC infectious diseases

Result: Among these detected mutations, only L74I, M46L, G190E and E138G may result in drug resistance directly.

Table: M46L

Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.

PMID: 25575025 2014 Retrovirology

Result: M46I and M46L in protease resulted in the most severe reduction of RC (Figure 1).

Result: We constructed recombinant viruses using patient-derived protease containing M46L, M46I or L90M, or patient-derived n-terminus of RT containing M41L or K103N into HXB2.

Result: We determined the impact of TDRM on viral RC by introducing frequently observed drug-resistance mutations M46I, M46L or L90M in protease or M41L, M41L +

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.

PMID: 25926858 2014 AIDS research and therapy

Result: At baseline, one or more primary PI RAMs were found in 10 patients (3%; nine treatment-naive, and one treatment-experienced), most commonly M46I/L (three treatment-naive and one treatment-experienced) and Q58E (four treatment-naive).

Browser Board

Co-occurred Entities

Filtrator